Graded Administration of Second Dose of Moderna and Pfizer-BioNTech COVID-19 mRNA Vaccines in Patients With Hypersensitivity to First Dose
Linh-An Tuong, Peter Capucilli, Mary L. Staicu, Allison Ramsey, Edward E. Walsh, S. Shahzad Mustafa
Abstract
Two mRNA coronavirus disease 2019 (COVID-19) vaccines, Moderna and Pfizer-BioNTech, require 2 doses for maximum efficacy. This case series reports the safety and immunogenicity of a graded administration of the second dose of the Moderna and Pfizer-BioNTech COVID-19 vaccines in patients with immediate hypersensitivity reactions to the first dose.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakAdministration (probate law)DermatologyVirologyPathologyDiseasePolitical scienceInfectious disease (medical specialty)LawOutbreakSARS-CoV-2 and COVID-19 ResearchDrug-Induced Adverse ReactionsInhalation and Respiratory Drug Delivery